-
公开(公告)号:US20070203131A1
公开(公告)日:2007-08-30
申请号:US11789304
申请日:2007-04-23
申请人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
IPC分类号: A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/454 , A61K31/433 , A61K31/4245
CPC分类号: C07D213/26 , A61K31/18 , A61K31/195 , A61K31/397 , A61K31/4245 , A61K31/433 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US20080261966A1
公开(公告)日:2008-10-23
申请号:US12024860
申请日:2008-02-01
申请人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
IPC分类号: A61K31/5375 , C07D231/10 , A61K31/415 , A61K31/18 , A61K31/421 , A61P37/00 , A61P29/00 , C12N5/00 , C07D263/30 , C07C311/00 , C07D295/00
CPC分类号: C07D213/26 , A61K31/4245 , A61K31/433 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US20120014997A1
公开(公告)日:2012-01-19
申请号:US13245568
申请日:2011-09-26
申请人: Solomon Ungashe , J.J. Wright , Andrew Pennell , Zheng Wei , Anita Melikan
发明人: Solomon Ungashe , J.J. Wright , Andrew Pennell , Zheng Wei , Anita Melikan
IPC分类号: A61K31/4409 , C07D413/12 , C07D213/84 , C07D213/89 , C07D213/71 , C07D239/26 , C07D405/12 , A61K31/4425 , A61K31/44 , A61K31/4439 , A61K31/505 , A61K31/4433 , A61K31/5377 , A61K31/635 , C12N5/0783 , A61P29/00 , A61P37/02 , A61P37/08 , A61P17/06 , A61P11/06 , A61P35/00 , A61P37/06 , A61P19/02 , A61P35/02 , C07D213/50
CPC分类号: C07D417/12 , A61K31/4409 , A61K31/443 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/26 , C07D213/50 , C07D213/52 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D239/26 , C07D241/12 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
公开(公告)号:US20050165067A1
公开(公告)日:2005-07-28
申请号:US11046565
申请日:2005-01-27
申请人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell
发明人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell
IPC分类号: A61P29/00 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12 , A61K31/455 , C07D213/46
CPC分类号: C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
-
公开(公告)号:US20110257183A1
公开(公告)日:2011-10-20
申请号:US13092615
申请日:2011-04-22
申请人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell , Brett Premack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , J.J. Wright , Andrew Pennell , Brett Premack , Thomas Schall
IPC分类号: A61K31/535 , C07C311/21 , A61K31/18 , A61K31/4406 , A61K31/381 , C07D211/72 , C07D333/08 , C07D307/87 , A61K31/343 , A61K31/415 , C07D231/12 , C07D263/32 , A61K31/421 , A61K31/24 , C07D265/30 , C12N5/02
CPC分类号: C07D213/26 , A61K31/4245 , A61K31/433 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US20110021523A1
公开(公告)日:2011-01-27
申请号:US12896114
申请日:2010-10-01
申请人: Solomon Ugashe , Zheng Wei , J.J. Wright , Andrew Pennell
发明人: Solomon Ugashe , Zheng Wei , J.J. Wright , Andrew Pennell
IPC分类号: A61K31/4439 , C07D413/12 , C07D213/50 , C07D239/26 , C07D413/04 , C07D213/70 , C07D241/12 , C07D213/84 , A61K31/4409 , A61K31/505 , A61K31/5377 , A61K31/44 , A61K31/4965 , A61P29/00 , A61P37/00 , A61P1/00 , A61P37/08 , A61P37/06 , A61P17/06 , A61P11/06 , A61P17/00 , A61P19/02 , A61P35/00 , A61P35/02
CPC分类号: C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
公开(公告)号:US20090118307A1
公开(公告)日:2009-05-07
申请号:US12251829
申请日:2008-10-15
申请人: Solomon Ugashe , Zheng Wei , J.J. Wright , Andrew Pennell
发明人: Solomon Ugashe , Zheng Wei , J.J. Wright , Andrew Pennell
IPC分类号: A61K31/4409 , C07D213/46 , C07D239/24 , A61K31/4965 , A61P1/00 , A61K31/505 , C07D403/06
CPC分类号: C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
公开(公告)号:US20090270616A1
公开(公告)日:2009-10-29
申请号:US12498633
申请日:2009-07-07
申请人: Solomon Ugashe , Zheng Wei , J.J. Wright , Andrew Pennell
发明人: Solomon Ugashe , Zheng Wei , J.J. Wright , Andrew Pennell
IPC分类号: C07D413/04 , C07D413/12 , C07D213/50
CPC分类号: C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
公开(公告)号:US20080293717A1
公开(公告)日:2008-11-27
申请号:US12166844
申请日:2008-07-02
申请人: SOLOMON UGASHE , Zheng Wei , J.J. Wright , Andrew Pennell
发明人: SOLOMON UGASHE , Zheng Wei , J.J. Wright , Andrew Pennell
IPC分类号: A61K31/5377 , A61K31/455 , A61K31/44 , C07D213/46 , C07D241/02 , A61P1/00 , A61K31/4965 , C07D413/00 , A61K31/505 , C07D239/02
CPC分类号: C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
公开(公告)号:US20060106218A1
公开(公告)日:2006-05-18
申请号:US11008774
申请日:2004-12-08
申请人: Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Brian McMaster , Daniel Dairaghi , Wei Chen , Penglie Zhang
发明人: Andrew Pennell , James Aggen , J.J. Wright , Subhabrata Sen , Brian McMaster , Daniel Dairaghi , Wei Chen , Penglie Zhang
IPC分类号: C07D403/02
CPC分类号: C07D403/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/38 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/16 , C07D249/08 , C07D249/14 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D473/34 , A61K2300/00
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
-
-
-
-
-
-
-
-
-